SCHEMBL4481541

SCHEMBL4481541

COC(=O)[C@@H]1CCCC[C@@H]1NC(=O)OCc1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CPB1 P15086 2/20 0.78
CTSB P07858 2/20 0.59
CTSS P25774 2/20 0.59
CTSK P43235 2/20 0.59
CTSL P07711 1/20 0.59
CASP3 P42574 3/20 0.58
TSHR P16473 2/20 0.53
EPHX1 P07099 1/20 0.53
ALDH1A1 P00352 3/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
CYP1A2 P05177 1/20 0.53
POLB P06746 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
GAA P10253 1/20 0.52
LMNA P02545 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10303639 1.00 CPB1 (0.78) CPB1CTSBCTSSCTSKCTSL
SCHEMBL28376595 1.00 CPB1 (0.78) CPB1CTSBCTSSCTSKCTSL
SCHEMBL26253812 0.99 CPB1 (0.76) CPB1CTSBCTSSCTSKCTSL
SCHEMBL14161287 0.97 CPB1 (0.78) CPB1CTSBCTSSCTSKCTSL
SCHEMBL13712268 0.97 CPB1 (0.78) CPB1CTSBCTSSCTSKCTSL
SCHEMBL23089809 0.92 CPB1 (0.90) CPB1CTSBCTSSCTSKCTSL
SCHEMBL2497897 0.92 CPB1 (0.90) CPB1CTSBCTSSCTSKCTSL
SCHEMBL12193443 0.92 CPB1 (0.90) CPB1CTSBCTSSCTSKCTSL
SCHEMBL30059391 0.92 CPB1 (0.90) CPB1CTSBCTSSCTSKCTSL
SCHEMBL30617864 0.91 CPB1 (0.66) CPB1CTSBCTSSCTSKCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
WO-2008073982-A2 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS HAVCR2, PYGL, HCCS CPB1 1589/4885CTSB 2044/4885CTSS 2278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.